Exact Mass: 408.1241

Exact Mass Matches: 408.1241

Found 18 metabolites which its exact mass value is equals to given mass value 408.1241, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid

2-Ethoxy-3-(4-{2-[4-(methanesulphonyloxy)phenyl]ethoxy}phenyl)propanoic acid

C20H24O7S (408.1243)


   

Podolactone D

Podolactone D

C20H24O7S (408.1243)


   

SR-Podolactone D

(+)-SR-Podolactone D

C20H24O7S (408.1243)


   
   

Zinc acexamate

epsilon-Acetamidocaproic acid zinc salt

C16H28N2O6Zn (408.1239)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

tesaglitazar

tesaglitazar

C20H24O7S (408.1243)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist

   
   

4-dimethoxyphosphoryl-2-(1-naphthalenyl)-N-(phenylmethyl)-5-oxazolamine

4-dimethoxyphosphoryl-2-(1-naphthalenyl)-N-(phenylmethyl)-5-oxazolamine

C22H21N2O4P (408.1239)


   
   

CCG-203971

CCG-203971

C23H21ClN2O3 (408.1241)


CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent[1][2].

   

(1s,2r,4s,5r,14r,17r)-5-[(2s)-2-hydroxy-1-[(r)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

(1s,2r,4s,5r,14r,17r)-5-[(2s)-2-hydroxy-1-[(r)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

C20H24O7S (408.1243)


   

(1s,2r,5r,14s,17r)-5-[(2r)-2-hydroxy-1-[(s)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

(1s,2r,5r,14s,17r)-5-[(2r)-2-hydroxy-1-[(s)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

C20H24O7S (408.1243)


   

(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-methanesulfinylpropan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-methanesulfinylpropan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

C20H24O7S (408.1243)


   

(1s,2r,4s,5r,10s,14r,17r)-5-[(2s)-2-hydroxy-1-[(r)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

(1s,2r,4s,5r,10s,14r,17r)-5-[(2s)-2-hydroxy-1-[(r)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

C20H24O7S (408.1243)


   

5-(2-hydroxy-1-methanesulfinylpropan-2-yl)-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

5-(2-hydroxy-1-methanesulfinylpropan-2-yl)-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

C20H24O7S (408.1243)


   

[(9s)-3,17-dihydroxy-16-methoxytricyclo[12.3.1.1²,⁶]nonadeca-1(17),2(19),3,5,14(18),15-hexaen-9-yl]oxidanesulfonic acid

[(9s)-3,17-dihydroxy-16-methoxytricyclo[12.3.1.1²,⁶]nonadeca-1(17),2(19),3,5,14(18),15-hexaen-9-yl]oxidanesulfonic acid

C20H24O7S (408.1243)


   

(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-[(s)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

(1s,2r,4s,5r,10s,14s,17r)-5-[(2r)-2-hydroxy-1-[(s)-methanesulfinyl]propan-2-yl]-10,14-dimethyl-3,6,16-trioxapentacyclo[8.6.1.0²,⁴.0⁴,⁹.0¹⁴,¹⁷]heptadeca-8,12-diene-7,15-dione

C20H24O7S (408.1243)